An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Icrucumab (Primary) ; Ramucirumab (Primary) ; Docetaxel
- Indications Bladder cancer; Pelvic cancer; Renal cancer; Urethral cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 29 Feb 2016 Results published in the Journal of Clinical Oncology
- 28 Sep 2015 Primary endpoint (Progression-free survival in patients treated with Ramucirumab +Docetaxel versus Docetaxel) has been met, according to an Eli Lilly media release.
- 28 Sep 2015 According to an Eli Lilly media release, results from this trial were presented at the the European Cancer Congress (ECC2015).